Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

In a phase 1 study, the seven patients given the highest dose tested reduced their weight by 5.3% on average after just 28 days of daily dosing ... candidate is called retatrutide, and it acts ...

Retatrutide targets GIP and GLP-1 – the same ... and type 2 diabetes will be finalised by the end of 2023. Twice-daily dosing would put danuglipron at a disadvantage to Lilly’s oral GLP ...

The prescribed dosage for fluoxetine may depend on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical history, may affect your ...

Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Objective: To determine ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company ...